Athos Therapeutics Announces the Completion of its Oversubscribed Series A Financing

LOS ANGELES: LOS ANGELES, Nov. 15, 2021 /PRNewswire/ -- Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, announced today the completion of an oversubscribed $15MM Series A financing. Athos Therapeutics completes an oversubscribed $15MM Series...

Click to view original post